In This Section

Program

Please note that this meeting will take place as an in-person event in Washington, D.C. and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the Registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program is subject to change. 

[R] – Remote Presentation
*-Short talk selected from proffered abstracts

thursday, october 6, 2022

Welcome and Opening Keynote Address

friday, october 7, 2022

Plenary Session 1: Structural and Chemical Biology of Chromatin Complexes
Plenary Session 2: Epigenetic Driver Mutations and Malignant Transformation
Plenary Session 3: Chromatin Associated RNA and its Modifications in Development and Disease
Plenary Session 4: Histone Modifications in Development and Disease
Proffered Talks I

saturday, october 8, 2022

Plenary Session 5: Chromatin Complexes in Cancer
Proffered Talks II
Plenary Session 6: 3D Genome and Extrachromosomal DNA
Plenary Session 7: Novel Therapeutic Approaches to Target Chromatin/Transcription

Thursday, october 6, 2022

CME Icon
Welcome and Opening Keynote ADDRESS
5:30–6:30 p.m.

Welcome from Cochairs

Title to be announced
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening Reception/POSTER SESSION A
6:30-9 p.m.    

FRIday, OCTOBER 7, 2022

continental breakfast
7-8 A.M.
CME Icon
Plenary Session 1: STRUCTURAL AND CHEMICAL BIOLOGY OF CHROMATIN COMPLEXES
8-9:30 a.m.

Structural basis of chromatin transcription
Lucas Farnung, Harvard Medical School, Boston, Massachusetts

Catalytic and non-catalytic mechanisms of histone lysine methyltransferases
Karim-Jean Armache, New York University Langone Health, New York, New York

Novel inhibitors of histone H2B deubiquitinating enzymes
Cynthia Wolberger, Johns Hopkins University, Baltimore, Maryland

Break
9:30-10 a.m.
CME Icon
Plenary Session 2: epigenetic driver mutations and malignant transformation
10–11:30 A.m.

Title to be announced
Margaret A. Goodell, Baylor College of Medicine, Houston, Texas

Title to be announced
Brian Huntly, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, England, United Kingdom

Transforming chromatin: Oncohistone mutations in pediatric high-grade glioma
Suzanne J. Baker, St. Jude Children’s Research Hospital, Memphis, Tennessee

Lunch (own)
11:30 a.m.-1 p.m.
CME Icon
Plenary Session 3: chromatin associated rna and its modifications in development and disease
1-2:30 p.m.

Chromatin regulation by reversible chromatin-associated RNA methylation
Chuan He, University of Chicago, Chicago, Illinois

Title to be announced
Sohail Tavazoie, The Rockefeller University, New York, New York

Title to be announced
John L. Rinn, University of Colorado Boulder, Boulder, Colorado

Break
2:30-3 p.m.                          
CME Icon
Plenary session 4: histone modifications in development and disease
3-4:30 p.m.

Title to be announced
Yang Shi, Oxford University, London, England, United Kingdom [R]

Epigenetic pathways in human health and disease
Shelley L. Berger, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

Title to be announced
Benjamin A. Garcia, Washington University School of Medicine in St. Louis, St. Louis, Missouri

break
4:30-5 p.m.
CME Icon
proffered talks I
5-6 p.m.
Reception/poster session B
6-8 p.m.

saturday, october 8, 2022

Continental breakfast
7-8 A.M.
CME Icon
Plenary Session 5: chromatin complexes in cancer
8-9:30 a.m.

SWI/SNF complexes in development and disease
Diana C. Hargreaves, Salk Institute, La Jolla, California

Principles of epigenetics and chromatin in development and human disease
Ali Shilatifard, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Characterization of the protein-protein interactions involved in DOT1L epigenetic regulation on biochemical, structural and functional level towards developing new therapeutic intervention
Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, Michigan

Break
9:30–9:45 a.m.
CME Icon
proffered talks II
9:45-10:45 A.m.
break
10:45–11 A.m.
CME Icon
Plenary Session 6: 3D GENOME AND EXTRACHROMOSOMAL DNA
11 a.m.-12:30 p.m.

Title to be announced
Bradley E. Bernstein, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Howard Y. Chang, Stanford University, Stanford, California

Ectopic levels of low-complexity domain interactions repress endogenous oncogenic transcription
Shasha Chong, California Institute of Technology, Pasadena, California

Break
12:30–1 p.m.
CME Icon
Plenary Session 7: NOVEL THERAPEUTIC APPROACHES TO TARGET CHROMATIN/TRANSCRIPTION
12:45-2:15 p.m.

Title to be announced
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts

Title to be announced
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Michigan

Aberrant transcriptional condensates in cancer: mechanisms and implications
Liling Wan, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

closing remarks and departure
2:15 p.m.

Times may change slightly as the program develops with the inclusion of short talks from proffered abstracts.